Internet-Based Relapse Prevention vs Face to Face Therapy at an Employee Assistance Program (FoBeMA)
Internet-Based Relapse Prevention With Therapist Support vs Face to Face Therapy at an Employee Assistance Program: A Randomized Controlled Non-inferiority Trial
Objectives: This study will evaluate the efficacy of internet-based relapse prevention with therapist support, as compared to face-to-face therapy at an employee assistance program. The design is a two-armed randomized controlled design, and outcomes are measured in terms of changes in problematic alcohol use, as well as depression and quality of life.
Method: Participants with problematic alcohol use who, after an initial evaluation consisting of five face-to-face sessions with a licensed psychologist where alcohol and collateral problems are extensively assessed, are recommended treatment for problematic alcohol use. Consenting participants will be randomized into one of two groups: 1. Internet delivered relapse prevention with therapist support or 2. Face-to-face therapy. Outcomes on alcohol use, depression and quality of life as well as information on user satisfaction will be gathered post treatment. Follow up will be at 3, 6 and 12 months after completion.
Our hypothesis is that the internet-based program with therapist support and the face-to-face therapy will be equally effective in reducing alcohol use (non-inferiority).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Stockholm, Suède, 171 76
- Karolinska Institutet, department of clinical neuroscience
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
Problematic alcohol use and having been recommended psychotherapy by the assessing psychologist.
Exclusion Criteria:
Inadequate Swedish language skills No Internet access Reading and/or writing difficulties Major depression Current suicidal thoughts and/or plans Primary problematic drug use PTSD-related problems Psychosis Cognitive disability
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: eChange web-based relapse prevention
A relapse intervention program consisting of 14 modules.
Patients will have access to therapist support through an internal secure messaging system.
|
A web-based relapse intervention program consisting of 14 modules.
The patient will have access to therapist support through a secure messaging system
|
|
Comparateur actif: Face-to-face therapy
Face-to-face psychotherapy, consisting of 20 sessions.
The content will be vary for different therapists, but all have an evidence-based approach to therapy
|
Face-to-face psychotherapy, consisting of 20 sessions.
The content will be different for different therapists, but all have an evidence based approach to therapy
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Alcohol Use Identification Test (AUDIT)
Délai: Post, 3, 6 and 12 months
|
Change in total AUDIT score, as a summarized measure of alcohol use (including alcohol consumption and alcohol-related problems)
|
Post, 3, 6 and 12 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time Line Follow Back (TLFB)
Délai: Post, 3, 6 and 12 months
|
Change in total TLFB score, as a summarized measure of alcohol consumption
|
Post, 3, 6 and 12 months
|
|
Montgomery Asberg Depression Rating Scale - Self report (MADRS-S)
Délai: Post, 3, 6 and 12 months
|
Change in total MADRS-S score, as a summarized measure of depression
|
Post, 3, 6 and 12 months
|
|
World Health Quality of Life Scale (WHOQOL-BREF)
Délai: Post, 3, 6 and 12 months
|
Change in total WHOQOL-BREF score, as a summarized measure of quality of life
|
Post, 3, 6 and 12 months
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Drug Use Identification Test (DUDIT)
Délai: Post, 3, 6 and 12 months
|
Change in total DUDIT score, as a summarized measure of drug (including alcohol consumption and alcohol-related problems)
|
Post, 3, 6 and 12 months
|
|
Biological tests for alcohol markers
Délai: Post
|
Biological marker outcomes post-treatment.
B-PEth and CDT.
|
Post
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Anne H Berman, PhD, Karolinska Institutet
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2013/1391-31/5
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .